HIV Diagnostics Market, 2028- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product (Consumables, Instruments, Software and Services), By Test Type (Antibody Tests(HIV-1 Screening Tests, HIV-1 Antibody Confirmatory Tests, HIV-2 & Group O Diagnostic Tests), Viral Load Tests, CD4 Test, Others), By Mode (Self-Test, Lab-based), By End-use (Diagnostic Laboratories, Hospitals & Clinics, Home Settings), By Region, By Competition Forecast & Opportunities, 2018-2028F.
Global HIV Diagnostics Market has valued at USD 3.96 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 7.42% through 2028. The global HIV diagnostics market has come a long way since the first reported cases of AIDS in the early 1980s. Over the years, significant advancements in diagnostics technologies, increased awareness, and improved accessibility to testing have played a crucial role in the global fight against HIV/AIDS. Today, the HIV diagnostics market is a dynamic and rapidly evolving sector, offering hope for better control and eventual eradication of this global health crisis.
HIV (Human Immunodeficiency Virus) is a virus that attacks the body's immune system, specifically targeting CD4 cells, which help the immune system fight off infections. Left untreated, HIV can lead to the disease AIDS (Acquired Immunodeficiency Syndrome), which makes the individual vulnerable to opportunistic infections and cancers. The global HIV epidemic remains a significant public health challenge, with millions of people living with HIV/AIDS worldwide. According to UNAIDS, approximately 38 million people were living with HIV in 2019. While progress has been made in reducing new infections and AIDS-related deaths, challenges persist, making accurate and accessible diagnostics a crucial aspect of the global response.
One of the most significant drivers of the HIV diagnostics market is continuous innovation in testing technologies. Traditional ELISA tests have given way to rapid point-of-care tests (POCTs) that provide quicker results. Advances in nucleic acid testing (NAT) and the development of novel biomarkers have also improved diagnostic accuracy. Increased awareness about HIV/AIDS has led to more individuals seeking testing services. Public health campaigns, educational initiatives, and destigmatization efforts have contributed to a more informed and proactive population. Governments and international organizations have played a pivotal role in expanding access to HIV testing. Funding for HIV diagnostics, especially in low- and middle-income countries, has improved testing infrastructure and accessibility. Early detection of HIV is essential for timely intervention and treatment. Routine testing, especially among high-risk populations, has become a cornerstone of HIV prevention and control strategies. International collaborations, such as the Joint United Nations Programme on HIV/AIDS (UNAIDS), have brought countries together to develop and implement comprehensive HIV/AIDS strategies, including diagnostics.
Key Market Drivers
Rising HIV Prevalence is Driving the Global HIV Diagnostics Market
The global HIV diagnostics market has witnessed significant growth in recent years, primarily driven by the rising prevalence of HIV/AIDS worldwide. HIV, or Human Immunodeficiency Virus, remains a global health challenge, with millions of people affected by the virus. As the need for early detection and management of HIV becomes increasingly crucial, the demand for advanced and efficient diagnostic tools has surged. HIV/AIDS remains a major public health issue, with the World Health Organization (WHO) estimating that approximately 38 million people were living with HIV in 2020. Sub-Saharan Africa is the most affected region, accounting for nearly two-thirds of all new HIV infections. However, the virus continues to impact individuals in every corner of the world, making it a global concern.
The increasing prevalence of HIV is a cause for concern. Despite considerable progress in prevention, treatment, and awareness, new infections continue to occur. In many regions, limited access to education, prevention measures, and contraceptives remains a challenge. This can result in higher rates of HIV transmission. Stigmatization of HIV-positive individuals and key populations, such as sex workers and men who have sex with men, often hinders efforts to prevent and control the virus. As the global population continues to grow, the absolute number of people living with HIV also increases. Insufficient awareness about HIV, its transmission, and prevention methods can lead to risky behaviors, contributing to new infections.
HIV diagnostics play a crucial role in the fight against HIV/AIDS. Timely and accurate diagnosis is essential for initiating antiretroviral therapy (ART), which can significantly improve the quality of life for individuals living with HIV and reduce the risk of transmission. Additionally, early detection helps prevent the progression of the virus to AIDS, thereby reducing mortality rates. The rising prevalence of HIV remains a significant global health challenge. However, it has also driven the growth of the HIV diagnostics market. Early and accurate diagnosis is critical for managing the virus, preventing transmission, and improving the quality of life for those affected. As the global healthcare community continues to address the HIV/AIDS pandemic, ongoing innovation in diagnostics will play a pivotal role in achieving the goal of an AIDS-free world.
Rising Demand for Early Diagnosis and Treatment Fuels Growth in Global HIV Diagnostics
The global HIV diagnostics market is experiencing significant growth, thanks to the increasing demand for early diagnosis and treatment of HIV (Human Immunodeficiency Virus). HIV remains a global health crisis, affecting millions of people worldwide. However, advancements in diagnostic technologies, increased awareness, and a growing emphasis on early detection have led to a surge in demand for HIV diagnostics. Early detection allows for the prompt initiation of antiretroviral therapy (ART), which can effectively suppress the virus, slow down disease progression, and improve the quality of life for those living with HIV.
People who are aware of their HIV status are more likely to take measures to prevent the transmission of the virus to others, such as using condoms and practicing safe injection practices. Knowledge of one's HIV status can help reduce the stigma associated with the virus, encouraging individuals to seek treatment and support. Early treatment not only extends the lifespan of individuals with HIV but also reduces the risk of developing opportunistic infections and AIDS-related complications. Increased awareness about the importance of HIV testing, along with public health campaigns and education efforts, has contributed to the rising demand for HIV diagnostics. Additionally, governments and international organizations have made efforts to make testing more accessible and affordable, especially in regions with high HIV prevalence.
Key Market Challenges
Limited Accessibility and Awareness Poses a Significant Obstacle To Market Expansion
One of the primary challenges in the global HIV diagnostics market is the limited accessibility to testing facilities, especially in remote and underserved regions. Additionally, a lack of awareness and stigma surrounding HIV can deter individuals from seeking testing and treatment. This issue is further exacerbated by socio-economic disparities, making it challenging to reach marginalized populations.
Solution: Governments, NGOs, and healthcare organizations should collaborate to establish more accessible and community-based testing centers, conduct awareness campaigns, and provide education to reduce HIV-related stigma.
High Costs
HIV diagnostics often come with high costs, which can be prohibitive for individuals in low and middle-income countries. The expensive equipment, reagents, and skilled personnel required for advanced diagnostics can strain healthcare budgets and limit access to testing.
Solution: Lowering the cost of HIV diagnostics through innovative technologies, bulk purchasing, and partnerships with manufacturers can help make testing more affordable, especially in resource-limited settings.
Rapidly Evolving Technology
The HIV diagnostics landscape is continuously evolving with new technologies and testing methods. Staying up-to-date with the latest advancements can be challenging for healthcare providers and organizations. This can lead to delays in implementing more accurate and efficient diagnostic tools.
Solution: Regular training and capacity-building programs for healthcare professionals can help them adapt to new technologies and stay informed about the latest diagnostic methods and trends.
False Positives and Negatives
False-positive and false-negative test results can have severe consequences. False positives can lead to unnecessary stress and stigmatization, while false negatives can delay crucial treatment and prevention measures. These errors can occur due to various factors, such as the window period during which the virus is not detectable.
Solution: Developing and implementing more accurate and reliable diagnostic tests, reducing the window period, and conducting confirmatory tests can help mitigate the risk of false results..
Supply Chain Disruptions
The COVID-19 pandemic highlighted the vulnerability of global supply chains, impacting the availability of HIV diagnostics and essential supplies. Disruptions in the supply chain can lead to shortages of test kits and reagents, affecting testing capabilities.
Solution: Diversifying suppliers and establishing strategic stockpiles of essential diagnostic components can help mitigate the risks associated with supply chain disruptions..
Regulatory Challenges
The HIV diagnostics market is subject to stringent regulations and quality control standards, which can pose barriers to market entry for new and innovative diagnostic technologies. Regulatory approvals can be time-consuming and costly, delaying the introduction of improved diagnostics.
Solution: Streamlining regulatory processes and providing incentives for the development of innovative HIV diagnostics can accelerate their approval and market availability..
Key Market Trends
Technological Advancements
One of the most significant advancements in HIV diagnostics is the development of point-of-care testing devices. These portable devices provide rapid results, often in less than 30 minutes, allowing for immediate initiation of treatment and reducing the risk of transmission. POCT devices have been a game-changer in resource-limited settings where access to sophisticated laboratory facilities is limited. NAT technologies have improved the accuracy of HIV diagnostics by directly detecting the virus's genetic material. These tests have a shorter window period, allowing for earlier detection of HIV infection. Additionally, NAT methods are highly sensitive, reducing the likelihood of false-negative results. NGS technologies have enabled researchers to study the genetic diversity of HIV strains. This information is crucial for developing more effective diagnostic tests and treatments, as HIV is known for its rapid mutation rate. Modern serological assays, such as chemiluminescence immunoassays and multiplex bead-based assays, have improved the accuracy and specificity of HIV antibody detection. These assays can distinguish between HIV-1 and HIV-2 and are less prone to false-positive results.
The global HIV diagnostics market has experienced substantial growth due to the demand for advanced testing methods. The market is expected to continue expanding as new technologies become more accessible and affordable. Point-of-care testing devices have made HIV testing more accessible, particularly in remote and underserved areas. This has been instrumental in reaching populations that were previously underserved in terms of HIV diagnosis and treatment. The continuous innovation in HIV diagnostics has spurred research and development efforts in both academia and industry. This has led to the creation of novel diagnostic tools and reagents, further advancing the market. Increased demand and technological advancements have led to fierce competition among diagnostic companies. This competition has driven companies to improve their products, resulting in better diagnostic accuracy and reduced costs.
Segmental Insights
Product Insights
Based on the category of Product, the consumables segment emerged as the dominant player in the global market for HIV Diagnostics in 2022. The consumables segment includes products like rapid diagnostic test kits, which have gained popularity due to their ease of use and quick results. These tests are often used in resource-limited settings, where access to more sophisticated diagnostic equipment may be limited. The demand for rapid HIV testing has driven the growth of the consumables market. HIV is a global health concern, with a significant burden in developing regions where access to healthcare infrastructure is limited. Consumables are often preferred in such regions due to their cost-effectiveness and suitability for point-of-care testing. As efforts to combat HIV continue to expand in these regions, the demand for consumables remains high. Advances in diagnostic technology have led to the development of more sensitive and specific HIV tests. These newer tests often require specialized consumables to function effectively. As healthcare providers and laboratories upgrade their testing capabilities, they invest in these consumables. Many governments and international organizations run HIV prevention and control programs that involve widespread testing campaigns. These initiatives often involve the procurement of consumables in large quantities, driving market demand. Consumables in the HIV diagnostics market are often competitively priced to cater to a broader customer base. This pricing strategy can stimulate demand and drive the dominance of this segment. The availability of HIV home testing kits has also contributed to the growth of the consumables segment. These kits typically include test strips or other consumables necessary for self-testing.
Mode Insights
The lab-based segment is projected to experience rapid growth during the forecast period. Lab-based tests for HIV diagnosis, such as enzyme immunoassays (EIAs) and nucleic acid tests (NATs), are known for their high accuracy and reliability. They have lower rates of false positives and false negatives compared to some rapid point-of-care tests. Accuracy is crucial in HIV diagnosis to ensure that individuals receive appropriate care and treatment. Lab-based testing allows for a more comprehensive evaluation of HIV infection. It can detect both HIV antibodies and viral RNA or DNA, providing a complete picture of the infection stage and viral load. This information is important for determining the appropriate treatment regimen and monitoring the progression of the disease. In many healthcare settings, lab-based tests are used to confirm positive results from rapid or point-of-care tests. Confirmatory testing helps reduce the chances of misdiagnosis and provides a definitive HIV diagnosis.
Regional Insights
Asia Pacific emerged as the dominant player in the global HIV Diagnostics market in 2022, holding the largest market share in terms of value. The Asia Pacific region has a significant burden of HIV/AIDS cases, with countries like India, China, Thailand, and Indonesia having large populations living with the virus. This high prevalence creates a substantial demand for HIV diagnostic tests and related healthcare services. The Asia Pacific region is home to a massive and diverse population, which provides a vast market for HIV diagnostic products and services. The sheer number of people in the region contributes to the high demand for testing and monitoring. Over the years, there has been a growing awareness of HIV/AIDS in the Asia Pacific region. Governments, NGOs, and healthcare organizations have undertaken various initiatives to encourage HIV testing, leading to increased demand for diagnostic tests.
Key Market Players
Thermo Fisher Scientific, Inc.
Alere Inc.
Abbott Laboratories inc.
Bristol-Myers Squibb Company
Janssen Global Services, LLC
Gilead Sciences, Inc.
Merck & Co. Inc.
VIIV Healthcare
Beckman Coulter, Inc.
Sysmex Europe SE
Zyomtronix, Inc.
Mylan N.V.
F. Hoffmann-La Roche Ltd.
Siemens Healthcare GmbH
Report Scope:
In this report, the Global Vitamins Supplements Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global HIV Diagnostics Market.
Available Customizations:
Global HIV Diagnostics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
HIV (Human Immunodeficiency Virus) is a virus that attacks the body's immune system, specifically targeting CD4 cells, which help the immune system fight off infections. Left untreated, HIV can lead to the disease AIDS (Acquired Immunodeficiency Syndrome), which makes the individual vulnerable to opportunistic infections and cancers. The global HIV epidemic remains a significant public health challenge, with millions of people living with HIV/AIDS worldwide. According to UNAIDS, approximately 38 million people were living with HIV in 2019. While progress has been made in reducing new infections and AIDS-related deaths, challenges persist, making accurate and accessible diagnostics a crucial aspect of the global response.
One of the most significant drivers of the HIV diagnostics market is continuous innovation in testing technologies. Traditional ELISA tests have given way to rapid point-of-care tests (POCTs) that provide quicker results. Advances in nucleic acid testing (NAT) and the development of novel biomarkers have also improved diagnostic accuracy. Increased awareness about HIV/AIDS has led to more individuals seeking testing services. Public health campaigns, educational initiatives, and destigmatization efforts have contributed to a more informed and proactive population. Governments and international organizations have played a pivotal role in expanding access to HIV testing. Funding for HIV diagnostics, especially in low- and middle-income countries, has improved testing infrastructure and accessibility. Early detection of HIV is essential for timely intervention and treatment. Routine testing, especially among high-risk populations, has become a cornerstone of HIV prevention and control strategies. International collaborations, such as the Joint United Nations Programme on HIV/AIDS (UNAIDS), have brought countries together to develop and implement comprehensive HIV/AIDS strategies, including diagnostics.
Key Market Drivers
Rising HIV Prevalence is Driving the Global HIV Diagnostics Market
The global HIV diagnostics market has witnessed significant growth in recent years, primarily driven by the rising prevalence of HIV/AIDS worldwide. HIV, or Human Immunodeficiency Virus, remains a global health challenge, with millions of people affected by the virus. As the need for early detection and management of HIV becomes increasingly crucial, the demand for advanced and efficient diagnostic tools has surged. HIV/AIDS remains a major public health issue, with the World Health Organization (WHO) estimating that approximately 38 million people were living with HIV in 2020. Sub-Saharan Africa is the most affected region, accounting for nearly two-thirds of all new HIV infections. However, the virus continues to impact individuals in every corner of the world, making it a global concern.
The increasing prevalence of HIV is a cause for concern. Despite considerable progress in prevention, treatment, and awareness, new infections continue to occur. In many regions, limited access to education, prevention measures, and contraceptives remains a challenge. This can result in higher rates of HIV transmission. Stigmatization of HIV-positive individuals and key populations, such as sex workers and men who have sex with men, often hinders efforts to prevent and control the virus. As the global population continues to grow, the absolute number of people living with HIV also increases. Insufficient awareness about HIV, its transmission, and prevention methods can lead to risky behaviors, contributing to new infections.
HIV diagnostics play a crucial role in the fight against HIV/AIDS. Timely and accurate diagnosis is essential for initiating antiretroviral therapy (ART), which can significantly improve the quality of life for individuals living with HIV and reduce the risk of transmission. Additionally, early detection helps prevent the progression of the virus to AIDS, thereby reducing mortality rates. The rising prevalence of HIV remains a significant global health challenge. However, it has also driven the growth of the HIV diagnostics market. Early and accurate diagnosis is critical for managing the virus, preventing transmission, and improving the quality of life for those affected. As the global healthcare community continues to address the HIV/AIDS pandemic, ongoing innovation in diagnostics will play a pivotal role in achieving the goal of an AIDS-free world.
Rising Demand for Early Diagnosis and Treatment Fuels Growth in Global HIV Diagnostics
The global HIV diagnostics market is experiencing significant growth, thanks to the increasing demand for early diagnosis and treatment of HIV (Human Immunodeficiency Virus). HIV remains a global health crisis, affecting millions of people worldwide. However, advancements in diagnostic technologies, increased awareness, and a growing emphasis on early detection have led to a surge in demand for HIV diagnostics. Early detection allows for the prompt initiation of antiretroviral therapy (ART), which can effectively suppress the virus, slow down disease progression, and improve the quality of life for those living with HIV.
People who are aware of their HIV status are more likely to take measures to prevent the transmission of the virus to others, such as using condoms and practicing safe injection practices. Knowledge of one's HIV status can help reduce the stigma associated with the virus, encouraging individuals to seek treatment and support. Early treatment not only extends the lifespan of individuals with HIV but also reduces the risk of developing opportunistic infections and AIDS-related complications. Increased awareness about the importance of HIV testing, along with public health campaigns and education efforts, has contributed to the rising demand for HIV diagnostics. Additionally, governments and international organizations have made efforts to make testing more accessible and affordable, especially in regions with high HIV prevalence.
Key Market Challenges
Limited Accessibility and Awareness Poses a Significant Obstacle To Market Expansion
One of the primary challenges in the global HIV diagnostics market is the limited accessibility to testing facilities, especially in remote and underserved regions. Additionally, a lack of awareness and stigma surrounding HIV can deter individuals from seeking testing and treatment. This issue is further exacerbated by socio-economic disparities, making it challenging to reach marginalized populations.
Solution: Governments, NGOs, and healthcare organizations should collaborate to establish more accessible and community-based testing centers, conduct awareness campaigns, and provide education to reduce HIV-related stigma.
High Costs
HIV diagnostics often come with high costs, which can be prohibitive for individuals in low and middle-income countries. The expensive equipment, reagents, and skilled personnel required for advanced diagnostics can strain healthcare budgets and limit access to testing.
Solution: Lowering the cost of HIV diagnostics through innovative technologies, bulk purchasing, and partnerships with manufacturers can help make testing more affordable, especially in resource-limited settings.
Rapidly Evolving Technology
The HIV diagnostics landscape is continuously evolving with new technologies and testing methods. Staying up-to-date with the latest advancements can be challenging for healthcare providers and organizations. This can lead to delays in implementing more accurate and efficient diagnostic tools.
Solution: Regular training and capacity-building programs for healthcare professionals can help them adapt to new technologies and stay informed about the latest diagnostic methods and trends.
False Positives and Negatives
False-positive and false-negative test results can have severe consequences. False positives can lead to unnecessary stress and stigmatization, while false negatives can delay crucial treatment and prevention measures. These errors can occur due to various factors, such as the window period during which the virus is not detectable.
Solution: Developing and implementing more accurate and reliable diagnostic tests, reducing the window period, and conducting confirmatory tests can help mitigate the risk of false results..
Supply Chain Disruptions
The COVID-19 pandemic highlighted the vulnerability of global supply chains, impacting the availability of HIV diagnostics and essential supplies. Disruptions in the supply chain can lead to shortages of test kits and reagents, affecting testing capabilities.
Solution: Diversifying suppliers and establishing strategic stockpiles of essential diagnostic components can help mitigate the risks associated with supply chain disruptions..
Regulatory Challenges
The HIV diagnostics market is subject to stringent regulations and quality control standards, which can pose barriers to market entry for new and innovative diagnostic technologies. Regulatory approvals can be time-consuming and costly, delaying the introduction of improved diagnostics.
Solution: Streamlining regulatory processes and providing incentives for the development of innovative HIV diagnostics can accelerate their approval and market availability..
Key Market Trends
Technological Advancements
One of the most significant advancements in HIV diagnostics is the development of point-of-care testing devices. These portable devices provide rapid results, often in less than 30 minutes, allowing for immediate initiation of treatment and reducing the risk of transmission. POCT devices have been a game-changer in resource-limited settings where access to sophisticated laboratory facilities is limited. NAT technologies have improved the accuracy of HIV diagnostics by directly detecting the virus's genetic material. These tests have a shorter window period, allowing for earlier detection of HIV infection. Additionally, NAT methods are highly sensitive, reducing the likelihood of false-negative results. NGS technologies have enabled researchers to study the genetic diversity of HIV strains. This information is crucial for developing more effective diagnostic tests and treatments, as HIV is known for its rapid mutation rate. Modern serological assays, such as chemiluminescence immunoassays and multiplex bead-based assays, have improved the accuracy and specificity of HIV antibody detection. These assays can distinguish between HIV-1 and HIV-2 and are less prone to false-positive results.
The global HIV diagnostics market has experienced substantial growth due to the demand for advanced testing methods. The market is expected to continue expanding as new technologies become more accessible and affordable. Point-of-care testing devices have made HIV testing more accessible, particularly in remote and underserved areas. This has been instrumental in reaching populations that were previously underserved in terms of HIV diagnosis and treatment. The continuous innovation in HIV diagnostics has spurred research and development efforts in both academia and industry. This has led to the creation of novel diagnostic tools and reagents, further advancing the market. Increased demand and technological advancements have led to fierce competition among diagnostic companies. This competition has driven companies to improve their products, resulting in better diagnostic accuracy and reduced costs.
Segmental Insights
Product Insights
Based on the category of Product, the consumables segment emerged as the dominant player in the global market for HIV Diagnostics in 2022. The consumables segment includes products like rapid diagnostic test kits, which have gained popularity due to their ease of use and quick results. These tests are often used in resource-limited settings, where access to more sophisticated diagnostic equipment may be limited. The demand for rapid HIV testing has driven the growth of the consumables market. HIV is a global health concern, with a significant burden in developing regions where access to healthcare infrastructure is limited. Consumables are often preferred in such regions due to their cost-effectiveness and suitability for point-of-care testing. As efforts to combat HIV continue to expand in these regions, the demand for consumables remains high. Advances in diagnostic technology have led to the development of more sensitive and specific HIV tests. These newer tests often require specialized consumables to function effectively. As healthcare providers and laboratories upgrade their testing capabilities, they invest in these consumables. Many governments and international organizations run HIV prevention and control programs that involve widespread testing campaigns. These initiatives often involve the procurement of consumables in large quantities, driving market demand. Consumables in the HIV diagnostics market are often competitively priced to cater to a broader customer base. This pricing strategy can stimulate demand and drive the dominance of this segment. The availability of HIV home testing kits has also contributed to the growth of the consumables segment. These kits typically include test strips or other consumables necessary for self-testing.
Mode Insights
The lab-based segment is projected to experience rapid growth during the forecast period. Lab-based tests for HIV diagnosis, such as enzyme immunoassays (EIAs) and nucleic acid tests (NATs), are known for their high accuracy and reliability. They have lower rates of false positives and false negatives compared to some rapid point-of-care tests. Accuracy is crucial in HIV diagnosis to ensure that individuals receive appropriate care and treatment. Lab-based testing allows for a more comprehensive evaluation of HIV infection. It can detect both HIV antibodies and viral RNA or DNA, providing a complete picture of the infection stage and viral load. This information is important for determining the appropriate treatment regimen and monitoring the progression of the disease. In many healthcare settings, lab-based tests are used to confirm positive results from rapid or point-of-care tests. Confirmatory testing helps reduce the chances of misdiagnosis and provides a definitive HIV diagnosis.
Regional Insights
Asia Pacific emerged as the dominant player in the global HIV Diagnostics market in 2022, holding the largest market share in terms of value. The Asia Pacific region has a significant burden of HIV/AIDS cases, with countries like India, China, Thailand, and Indonesia having large populations living with the virus. This high prevalence creates a substantial demand for HIV diagnostic tests and related healthcare services. The Asia Pacific region is home to a massive and diverse population, which provides a vast market for HIV diagnostic products and services. The sheer number of people in the region contributes to the high demand for testing and monitoring. Over the years, there has been a growing awareness of HIV/AIDS in the Asia Pacific region. Governments, NGOs, and healthcare organizations have undertaken various initiatives to encourage HIV testing, leading to increased demand for diagnostic tests.
Key Market Players
Thermo Fisher Scientific, Inc.
Alere Inc.
Abbott Laboratories inc.
Bristol-Myers Squibb Company
Janssen Global Services, LLC
Gilead Sciences, Inc.
Merck & Co. Inc.
VIIV Healthcare
Beckman Coulter, Inc.
Sysmex Europe SE
Zyomtronix, Inc.
Mylan N.V.
F. Hoffmann-La Roche Ltd.
Siemens Healthcare GmbH
Report Scope:
In this report, the Global Vitamins Supplements Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Vitamins Supplements Market, By Product:
- Consumables
- Instruments
- Software and Services
- Vitamins Supplements Market, By Test Type:
- Antibody Tests
- Viral Load Tests
- CD4 Test
- Others
- Vitamins Supplements Market, By Mode:
- =
- Self-Test
- Lab-based
- Vitamins Supplements Market, By End Use:
- Diagnostic Laboratories
- Hospitals & Clinics
- Home Settings
- Vitamins Supplements Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global HIV Diagnostics Market.
Available Customizations:
Global HIV Diagnostics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
4. VOICE OF CUSTOMER
5. GLOBAL HIV DIAGNOSTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Consumables, Instruments, Software and Services)
5.2.2. By Test Type (Antibody Tests(HIV-1 Screening Tests, HIV-1 Antibody Confirmatory Tests, HIV-2 & Group O Diagnostic Tests), Viral Load Tests, CD4 Test, Others)
5.2.3. By Mode (Self-Test, Lab-based)
5.2.4. By End-use (Diagnostic Laboratories, Hospitals & Clinics, Home Settings)
5.2.5. By Region
5.2.6. By Company (2022)
5.3. Market Map
6. NORTH AMERICA HIV DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Test Type
6.2.3. By Mode
6.2.4. By End-Use
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States HIV Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Test Type
6.3.1.2.3. By Mode
6.3.1.2.4. By End-Use
6.3.2. Canada HIV Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Test Type
6.3.2.2.3. By Mode
6.3.2.2.4. By End-Use
6.3.3. Mexico HIV Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Test Type
6.3.3.2.3. By Mode
6.3.3.2.4. By End-Use
7. EUROPE HIV DIAGNOSTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Test Type
7.2.3. By Mode
7.2.4. By End-Use
7.3. Europe: Country Analysis
7.3.1. Germany HIV Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Test Type
7.3.1.2.3. By Mode
7.3.1.2.4. By End-Use
7.3.2. United Kingdom HIV Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Test Type
7.3.2.2.3. By Mode
7.3.2.2.4. By End-Use
7.3.3. Italy HIV Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Product
7.3.3.2.2. By Test Type
7.3.3.2.3. By Mode
7.3.3.2.4. By End-Use
7.3.4. France HIV Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Test Type
7.3.4.2.3. By Mode
7.3.4.2.4. By End-Use
7.3.5. Spain HIV Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Test Type
7.3.5.2.3. By Mode
7.3.5.2.4. By End-Use
8. ASIA-PACIFIC HIV DIAGNOSTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Test Type
8.2.3. By Mode
8.2.4. By End-Use
8.3. Asia-Pacific: Country Analysis
8.3.1. China HIV Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Test Type
8.3.1.2.3. By Mode
8.3.1.2.4. By End-Use
8.3.2. India HIV Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Test Type
8.3.2.2.3. By Mode
8.3.2.2.4. By End-Use
8.3.3. Japan HIV Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Test Type
8.3.3.2.3. By Mode
8.3.3.2.4. By End-Use
8.3.4. South Korea HIV Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Test Type
8.3.4.2.3. By Mode
8.3.4.2.4. By End-Use
8.3.5. Australia HIV Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Test Type
8.3.5.2.3. By Mode
8.3.5.2.4. By End-Use
9. SOUTH AMERICA HIV DIAGNOSTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Test Type
9.2.3. By Mode
9.2.4. By End-Use
9.3. South America: Country Analysis
9.3.1. Brazil HIV Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Test Type
9.3.1.2.3. By Mode
9.3.1.2.4. By End-Use
9.3.2. Argentina HIV Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Test Type
9.3.2.2.3. By Mode
9.3.2.2.4. By End-Use
9.3.3. Colombia HIV Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Test Type
9.3.3.2.3. By Mode
9.3.3.2.4. By End-Use
10. MIDDLE EAST AND AFRICA HIV DIAGNOSTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Test Type
10.2.3. By Mode
10.2.4. By End-Use
10.3. MEA: Country Analysis
10.3.1. South Africa HIV Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Test Type
10.3.1.2.3. By Mode
10.3.1.2.4. By End-Use
10.3.2. Saudi Arabia HIV Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Test Type
10.3.2.2.3. By Mode
10.3.2.2.4. By End-Use
10.3.3. UAE HIV Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Test Type
10.3.3.2.3. By Mode
10.3.3.2.4. By End-Use
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition
12.2. Product Development
12.3. Recent Developments
13. GLOBAL HIV DIAGNOSTICS MARKET: SWOT ANALYSIS
14. COMPETITIVE LANDSCAPE
14.1. Business Overview
14.2. Test Type Offerings
14.3. Recent Developments
14.4. Key Personnel
14.5. SWOT Analysis
14.5.1. Thermo Fisher Scientific, Inc.
14.5.2. Alere Inc.
14.5.3. Abbott Laboratories inc.
14.5.4. Bristol-Myers Squibb Company
14.5.5. Janssen Global Services, LLC
14.5.6. Gilead Sciences, Inc.
14.5.7. Merck & Co. Inc.
14.5.8. VIIV Healthcare
14.5.9. Beckman Coulter, Inc.
14.5.10. Sysmex Europe SE
14.5.11. Zyomtronix, Inc.
14.5.12. Mylan N.V.
14.5.13. F. Hoffmann-La Roche Ltd.
14.5.14. Siemens Healthcare GmbH
15. STRATEGIC RECOMMENDATIONS
About Us & Disclaimer
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
4. VOICE OF CUSTOMER
5. GLOBAL HIV DIAGNOSTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Consumables, Instruments, Software and Services)
5.2.2. By Test Type (Antibody Tests(HIV-1 Screening Tests, HIV-1 Antibody Confirmatory Tests, HIV-2 & Group O Diagnostic Tests), Viral Load Tests, CD4 Test, Others)
5.2.3. By Mode (Self-Test, Lab-based)
5.2.4. By End-use (Diagnostic Laboratories, Hospitals & Clinics, Home Settings)
5.2.5. By Region
5.2.6. By Company (2022)
5.3. Market Map
6. NORTH AMERICA HIV DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Test Type
6.2.3. By Mode
6.2.4. By End-Use
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States HIV Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Test Type
6.3.1.2.3. By Mode
6.3.1.2.4. By End-Use
6.3.2. Canada HIV Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Test Type
6.3.2.2.3. By Mode
6.3.2.2.4. By End-Use
6.3.3. Mexico HIV Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Test Type
6.3.3.2.3. By Mode
6.3.3.2.4. By End-Use
7. EUROPE HIV DIAGNOSTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Test Type
7.2.3. By Mode
7.2.4. By End-Use
7.3. Europe: Country Analysis
7.3.1. Germany HIV Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Test Type
7.3.1.2.3. By Mode
7.3.1.2.4. By End-Use
7.3.2. United Kingdom HIV Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Test Type
7.3.2.2.3. By Mode
7.3.2.2.4. By End-Use
7.3.3. Italy HIV Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Product
7.3.3.2.2. By Test Type
7.3.3.2.3. By Mode
7.3.3.2.4. By End-Use
7.3.4. France HIV Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Test Type
7.3.4.2.3. By Mode
7.3.4.2.4. By End-Use
7.3.5. Spain HIV Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Test Type
7.3.5.2.3. By Mode
7.3.5.2.4. By End-Use
8. ASIA-PACIFIC HIV DIAGNOSTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Test Type
8.2.3. By Mode
8.2.4. By End-Use
8.3. Asia-Pacific: Country Analysis
8.3.1. China HIV Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Test Type
8.3.1.2.3. By Mode
8.3.1.2.4. By End-Use
8.3.2. India HIV Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Test Type
8.3.2.2.3. By Mode
8.3.2.2.4. By End-Use
8.3.3. Japan HIV Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Test Type
8.3.3.2.3. By Mode
8.3.3.2.4. By End-Use
8.3.4. South Korea HIV Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Test Type
8.3.4.2.3. By Mode
8.3.4.2.4. By End-Use
8.3.5. Australia HIV Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Test Type
8.3.5.2.3. By Mode
8.3.5.2.4. By End-Use
9. SOUTH AMERICA HIV DIAGNOSTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Test Type
9.2.3. By Mode
9.2.4. By End-Use
9.3. South America: Country Analysis
9.3.1. Brazil HIV Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Test Type
9.3.1.2.3. By Mode
9.3.1.2.4. By End-Use
9.3.2. Argentina HIV Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Test Type
9.3.2.2.3. By Mode
9.3.2.2.4. By End-Use
9.3.3. Colombia HIV Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Test Type
9.3.3.2.3. By Mode
9.3.3.2.4. By End-Use
10. MIDDLE EAST AND AFRICA HIV DIAGNOSTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Test Type
10.2.3. By Mode
10.2.4. By End-Use
10.3. MEA: Country Analysis
10.3.1. South Africa HIV Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Test Type
10.3.1.2.3. By Mode
10.3.1.2.4. By End-Use
10.3.2. Saudi Arabia HIV Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Test Type
10.3.2.2.3. By Mode
10.3.2.2.4. By End-Use
10.3.3. UAE HIV Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Test Type
10.3.3.2.3. By Mode
10.3.3.2.4. By End-Use
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition
12.2. Product Development
12.3. Recent Developments
13. GLOBAL HIV DIAGNOSTICS MARKET: SWOT ANALYSIS
14. COMPETITIVE LANDSCAPE
14.1. Business Overview
14.2. Test Type Offerings
14.3. Recent Developments
14.4. Key Personnel
14.5. SWOT Analysis
14.5.1. Thermo Fisher Scientific, Inc.
14.5.2. Alere Inc.
14.5.3. Abbott Laboratories inc.
14.5.4. Bristol-Myers Squibb Company
14.5.5. Janssen Global Services, LLC
14.5.6. Gilead Sciences, Inc.
14.5.7. Merck & Co. Inc.
14.5.8. VIIV Healthcare
14.5.9. Beckman Coulter, Inc.
14.5.10. Sysmex Europe SE
14.5.11. Zyomtronix, Inc.
14.5.12. Mylan N.V.
14.5.13. F. Hoffmann-La Roche Ltd.
14.5.14. Siemens Healthcare GmbH
15. STRATEGIC RECOMMENDATIONS
About Us & Disclaimer
